Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine: A Randomized Clinical Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Age 18 and 65 years.
• Both sexes.
• Chronic migraine. Chronic migraine, defined as headaches on ≥15 days per month for ≥3 months, of which ≥8 days meet criteria for migraine without aura or respond to migraine-specific treatment according to International Classification of Headache Disorders-3 Beta.
Locations
Other Locations
Egypt
Cairo University
RECRUITING
Cairo
Contact Information
Primary
Mohamed E Abdel Fattah, MD
mohamed-elsaid@cu.edu.eg
00201284475792
Time Frame
Start Date: 2025-05-15
Estimated Completion Date: 2025-10-01
Participants
Target number of participants: 64
Treatments
Experimental: Sphenopalatine block group
Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.
Experimental: BOTOX group
Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.
Related Therapeutic Areas
Sponsors
Leads: Cairo University